New Treatment Options for Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab

 

 Buy Article Permissions and Reprints

ABSTRACT

Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and renal impairment. Often HUS is triggered by Shiga-like toxin- producing Escherichia coli. Less common is atypical HUS (aHUS), which is caused by defective complement control. aHUS is associated with mutations in genes encoding complement regulatory proteins in ~50% of patients with this syndrome. Furthermore, autoantibodies that inactivate to factor H have also been linked to the disease. Initial triggers include infections, use of endothelial-affecting drugs, malignancies, transplantation, and pregnancy. Advances in our understanding of the pathogenesis of atypical HUS suggest that complement inhibition may be used as treatment for the disease. We discuss the potential benefit of the complement inhibitor eculizumab for the treatment of aHUS.

REFERENCES

• 1 Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  361(17) 1676-1687
  CrossrefPubMedGoogle Scholar
• 2 Noris M, Remuzzi G. Hemolytic uremic syndrome.  J Am Soc Nephrol. 2005;  16(4) 1035-1050
  CrossrefPubMedGoogle Scholar
• 3 Jokiranta T S, Zipfel P F, Frémeaux-Bacchi V, Taylor C M, Goodship T J, Noris M. Where next with atypical hemolytic uremic syndrome?.  Mol Immunol. 2007;  44(16) 3889-3900
  CrossrefPubMedGoogle Scholar
• 4 Atkinson J P, Goodship T H. Complement factor H and the hemolytic uremic syndrome.  J Exp Med. 2007;  204(6) 1245-1248
  CrossrefPubMedGoogle Scholar
• 5 Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children.  Pediatr Nephrol. 2008;  23(11) 1957-1972
  CrossrefPubMedGoogle Scholar
• 6 Thomas T C, Rollins S A, Rother R P et al. Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv.  Mol Immunol. 1996;  33(17-18) 1389-1401
  CrossrefPubMedGoogle Scholar
• 7 Hillmen P, Hall C, Marsh J C et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.  N Engl J Med. 2004;  350(6) 552-559
  CrossrefPubMedGoogle Scholar
• 8 Hillmen P, Young N S, Schubert J et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.  N Engl J Med. 2006;  355(12) 1233-1243
  CrossrefPubMedGoogle Scholar
• 9 Shin J I, Lee J S. More on eculizumab for congenital atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(20) 2142-2143; author reply 2143
  CrossrefPubMedGoogle Scholar
• 10 Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 542-544
  CrossrefPubMedGoogle Scholar
• 11 Gruppo R A, Rother R P. Eculizumab for congenital atypical hemolytic-uremic syndrome.  N Engl J Med. 2009;  360(5) 544-546
  CrossrefPubMedGoogle Scholar
• 12 Mache C J, Acham-Roschitz B, Frémeaux-Bacchi V et al. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome.  Clin J Am Soc Nephrol. 2009;  4(8) 1312-1316
  CrossrefPubMedGoogle Scholar
• 13 Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome.  Am J Transplant. 2009;  9(11) 2644-2645
  CrossrefPubMedGoogle Scholar
• 14 Davin J C, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.  Am J Kidney Dis. 2010;  55(4) 708-711
  CrossrefPubMedGoogle Scholar

PD Dr. med. J. Nürnberger

Department of Nephrology, University Hospital of Essen

University Duisburg-Essen, Hufelandstrasse 55, 45122 Essen, Germany

Email: jens.nuernberger@uni-due.de